BioNTech SE
$20.26B- Market cap
- $26.06B
- Debt
- +$2.68B
- Cash
- −$7.68B
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $26.06B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: BNTX stock price near parity vs DXCM $103.76 current versus $94.47 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DXCM's multiple
Implied fair value · at BNTX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BNTX FY 2025 (ended Dec 31, 2025) · DXCM FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 91% equity / 9% debt · EV / Revenue 6.07x
Capital structure 91% equity / 9% debt · EV / Revenue 7.63x · EV / EBITDA 26.75x
DXCM carries the larger enterprise value at $35.57B against $20.26B; BNTX trades on the lower EV / Revenue multiple (6.07x vs 7.63x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BioNTech SE · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
DEXCOM, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
1.21x
Net debt / EBITDA
Leverage against operating earnings
4.45x
1.81x
Cash and equivalents
Liquid reserves on the balance sheet
$7.68B
$917.70M
Total debt
Interest-bearing obligations outstanding
$2.68B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
BNTX vs MRNA
GILEAD SCIENCES, INC.
BNTX vs GILD
AMGEN INC
BNTX vs AMGN
REGENERON PHARMACEUTICALS, INC.
BNTX vs REGN
INCYTE CORP
BNTX vs INCY
VERTEX PHARMACEUTICALS INC / MA
BNTX vs VRTX
ABBOTT LABORATORIES
BNTX vs ABT
Medtronic plc
BNTX vs MDT
BECTON DICKINSON & CO
BNTX vs BDX
$3.32B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.